In the STEP 1 trial, participants lost an average of nearly 15% of their body weight over 68 weeks, helping establish semaglutide as one of the most effective weight-loss medications available at the time
Understanding this journey is not merely a pharmacokinetic exercise but is fundamental to explaining the disparate outcomes observed in clinical trials and for designing precision-based interventions
References Seladi-Schulman, Ph.D., Jill
"Prescription medications are highly targeted and have been through rigorous testing and clinical trials
Research has focused on this combinations role in GH pulse generation, IGF-1 axis modulation, and the downstream anabolic and metabolic effects of dual-pathway GH stimulation with comparative research designs using this blend alongside individual compounds such as CJC-1295 No DAC, Ipamorelin, and Tesamorelin allowing systematic dissection of GH axis pharmacology